“Mike has significant experience building and transforming high-potential technology growth companies into global market leaders,” Jeff Aronin, Evozyne co-founder and executive chairman, said in the statement. “His talents and leadership qualities make him an ideal CEO to build upon Evozyne’s early success and foster its commercial growth.”
The startup’s next phase will be in “aligning its scientific potential with optimal commercial growth,” the statement said.
Evozyne, founded in 2020 by Paragon Biosciences, develops proteins for gene therapies, antibody discovery and, potentially, sustainability applications, the company stated. In April 2022, the company entered into a research and licensing deal with drugmaker Takeda Pharmaceutical that could be worth more than $400 million.
Gamson also served as a senior vice president at LinkedIn. He was at LinkedIn for 11 years, where he led teams across 30 offices worldwide and grew revenue from tens of millions to multiple billions, Evozyne said in the statement.
“I am grateful to be a part of this talented team working together to unleash the power of Evozyne’s amazing protein-optimization technology to make a healthier, more sustainable world,” he said in the statement.
In October, Zach Serber joined Evozyne in the newly created position of chief operating officer. He was formerly chief scientific officer and co-founder of Zymergen and director of biology at Amyris.
Chicago-based Paragon Biosciences creates biology-based companies in the areas of cell and gene therapy, adaptive biology and advanced biotechnology. Its portfolio of companies includes Evozyne, Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Harmony Biosciences and Qlarity Imaging. Aronin is founder, chairman and CEO of Paragon and served as Evozyne’s CEO before Gamson.
